PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
USA - NASDAQ:PRVA - US74276R1023 - Common Stock
22.28 USD
+0.07 (+0.32%)
Taking everything into account, PRVA scores 4 out of 10 in our fundamental rating. PRVA was compared to 101 industry peers in the Health Care Providers & Services industry. While PRVA seems to be doing ok healthwise, there are quite some concerns on its profitability. PRVA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
PRVA had a positive operating cash flow in the past year.
In multiple years PRVA reported negative net income over the last 5 years.
In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
PRVA has a Return On Assets (1.17%) which is in line with its industry peers.
PRVA has a Return On Equity (2.17%) which is comparable to the rest of the industry.
The Return On Invested Capital of PRVA (1.78%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROIC | 1.78% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA has a Profit Margin of 0.78%. This is comparable to the rest of the industry: PRVA outperforms 53.47% of its industry peers.
PRVA's Profit Margin has declined in the last couple of years.
The Operating Margin of PRVA (1.03%) is comparable to the rest of the industry.
PRVA's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 9.96%, PRVA is not doing good in the industry: 72.28% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
Compared to 1 year ago, PRVA has more shares outstanding
PRVA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.46 indicates that PRVA is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.46, PRVA is doing good in the industry, outperforming 75.25% of the companies in the same industry.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.46 |
ROIC/WACC0.2
WACC8.68%
2.3 Liquidity
PRVA has a Current Ratio of 1.65. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.65, PRVA is in line with its industry, outperforming 55.45% of the companies in the same industry.
A Quick Ratio of 1.65 indicates that PRVA should not have too much problems paying its short term obligations.
PRVA has a Quick ratio of 1.65. This is comparable to the rest of the industry: PRVA outperforms 58.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased by -8.33% in the last year.
The Earnings Per Share has been growing slightly by 7.43% on average over the past years.
The Revenue has grown by 12.05% in the past year. This is quite good.
PRVA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.17% yearly.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
3.2 Future
The Earnings Per Share is expected to grow by 59.10% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 2.19% on average over the next years.
EPS Next Y50.02%
EPS Next 2Y72.07%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue Next Year15.92%
Revenue Next 2Y12.95%
Revenue Next 3Y12.82%
Revenue Next 5Y2.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 202.55, PRVA can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as PRVA.
PRVA is valuated expensively when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 68.41, which means the current valuation is very expensive for PRVA.
The rest of the industry has a similar Price/Forward Earnings ratio as PRVA.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, PRVA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 202.55 | ||
| Fwd PE | 68.41 |
4.2 Price Multiples
60.40% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
PRVA's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.23 | ||
| EV/EBITDA | 84.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 59.10% in the coming years.
PEG (NY)4.05
PEG (5Y)27.24
EPS Next 2Y72.07%
EPS Next 3Y59.1%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PRVA (9/18/2025, 9:51:06 AM)
22.28
+0.07 (+0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.78%
Inst Owner Change-2.09%
Ins Owners1.87%
Ins Owner Change-0.26%
Market Cap2.73B
Analysts84.29
Price Target31.19 (39.99%)
Short Float %2.59%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.4%
Min EPS beat(2)-60.96%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-44.58%
Min EPS beat(4)-60.96%
Max EPS beat(4)-37.83%
EPS beat(8)0
Avg EPS beat(8)-41.13%
EPS beat(12)4
Avg EPS beat(12)50.02%
EPS beat(16)7
Avg EPS beat(16)58.25%
Revenue beat(2)2
Avg Revenue beat(2)3.24%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.73%
Revenue beat(4)4
Avg Revenue beat(4)3.97%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)3.27%
Revenue beat(12)9
Avg Revenue beat(12)-4.22%
Revenue beat(16)10
Avg Revenue beat(16)-9.82%
PT rev (1m)-0.07%
PT rev (3m)-0.07%
EPS NQ rev (1m)1.01%
EPS NQ rev (3m)-31.27%
EPS NY rev (1m)-21.35%
EPS NY rev (3m)-21.89%
Revenue NQ rev (1m)6.16%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)3.72%
Revenue NY rev (3m)3.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 202.55 | ||
| Fwd PE | 68.41 | ||
| P/S | 1.44 | ||
| P/FCF | 28.23 | ||
| P/OCF | 29.77 | ||
| P/B | 4 | ||
| P/tB | 8.03 | ||
| EV/EBITDA | 84.24 |
EPS(TTM)0.11
EY0.49%
EPS(NY)0.33
Fwd EY1.46%
FCF(TTM)0.79
FCFY3.54%
OCF(TTM)0.75
OCFY3.36%
SpS15.48
BVpS5.56
TBVpS2.77
PEG (NY)4.05
PEG (5Y)27.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROCE | 2.66% | ||
| ROIC | 1.78% | ||
| ROICexc | 3.77% | ||
| ROICexgc | 251.71% | ||
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% | ||
| FCFM | 5.1% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score5
Asset Turnover1.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 77.53 | ||
| Cash Conversion | 331.3% | ||
| Profit Quality | 652.71% | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 | ||
| Altman-Z | 4.46 |
F-Score5
WACC8.68%
ROIC/WACC0.2
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
EPS Next Y50.02%
EPS Next 2Y72.07%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
Revenue Next Year15.92%
Revenue Next 2Y12.95%
Revenue Next 3Y12.82%
Revenue Next 5Y2.19%
EBIT growth 1Y52.75%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year514.99%
EBIT Next 3Y106.08%
EBIT Next 5Y64.83%
FCF growth 1Y145.73%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y132.44%
OCF growth 3Y25.67%
OCF growth 5Y35.01%